Brand-name drug
BuTrans price, strengths & recalls
Brand of buprenorphine (generic)
Pharmacies pay $83,752.68 for 672 hs of BuTrans 0.015 mg/hr (168 hr) patch this week, and from $32,828.47 to $88,083.11 across its 5 priced strengths and forms. The generic, buprenorphine, costs pharmacies from $8.62. It has 27 recalls on record, none ongoing. Its official label last changed on May 13, 2026.
Brand- Fair cash price
- $96,326.08
- Strengths
- 5
- Makers
- 1
- Updated
- Nov 11
BuTrans price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.005 mg/hr (168 hr) patch Brand | $48.85 | $32,828.47 / 672 hs |
| 0.0075 mg/hr (168 hr) patch Brand | $68.73 | $46,184.18 / 672 hs |
| 0.01 mg/hr (168 hr) patch Brand | $73.55 | $49,428.56 / 672 hs |
| 0.015 mg/hr (168 hr) patch Brand | $124.63 | $83,752.68 / 672 hs |
| 0.02 mg/hr (168 hr) patch Brand | $131.08 | $88,083.11 / 672 hs |
BuTrans vs generic buprenorphine
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
| Strength | Brand | Generic | Brand costs |
|---|---|---|---|
| 0.005 mg/hr (168 hr) patch | $32,828.47 | $16,185.10 | 2x |
| 0.0075 mg/hr (168 hr) patch | $46,184.18 | $25,661.58 | 1.8x |
| 0.01 mg/hr (168 hr) patch | $49,428.56 | $22,794.22 | 2.2x |
| 0.015 mg/hr (168 hr) patch | $83,752.68 | $33,942.87 | 2.5x |
| 0.02 mg/hr (168 hr) patch | $88,083.11 | $39,564.98 | 2.2x |
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 27 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for BuTrans
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use BUTRANS® safely and effectively. See full prescribing information for BUTRANS. BUTRANS® (buprenorphine) transdermal system, CIIIInitial U.S. Approval: 1981
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUTRANS
Addiction, Abuse, and Misuse
Because the use of BUTRANS® exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)].
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of BUTRANS, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BUTRANS are essential. Misuse or abuse of BUTRANS by chewing, swallowing, snorting or injecting buprenorphine extracted from the transdermal system will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death [see Warnings and Precautions (5.2)].
Accidental Exposure
Accidental exposure of even one dose of BUTRANS, especially in children, can result in a fatal overdose of buprenorphine [see Warnings and Precautions (5.2)].
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of BUTRANS and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)].
Neonatal Opioid Withdrawal Syndrome (NOWS)
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4)].
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)].
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUTRANS
See full prescribing information for complete boxed warning.
BUTRANS exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (5.1, 10)
Serious, life-threatening or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BUTRANS are essential. Instruct patients on proper administration of BUTRANS to reduce the risk. (2.1, 5.2)
Accidental exposure to BUTRANS, especially in children, can result in fatal overdose of buprenorphine. (5.2)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.4)
Healthcare providers are strongly encouraged to complete a REMS- compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.5)
Recent major changes (as listed on the label)
Boxed Warning | 12/2025 |
Indications and Usage (1) | 12/2025 |
Dosage and Administration (2.2, 2.3, 2.5) | 12/2025 |
Warnings and Precautions (5.1, 5.2, 5.3 5.15, 5.19) | 12/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA021306 · Knoa Pharma
- First approved
- June 30, 2010 (16 years ago)
- Latest approved change
- June 18, 2026
- Approved label
- PDF, Jan 6, 2026
- Generic makers
- 17 approved generic applications on the market
BuTrans questions
How much does butrans cost without insurance?
Pharmacies pay about $83,752.68 for 672 hs of butrans 0.015 mg/hr (168 hr) patch ($124.63 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $96,326.08. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for BuTrans?
Yes: buprenorphine. Pharmacies pay from $8.62 for it. Compare buprenorphine prices.
Is butrans in shortage?
No shortage is reported for butrans right now. We check the national shortage list every day.
Has butrans been recalled?
27 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the butrans label last change?
The official label was last updated on May 13, 2026 (version 32). See what changed.
Talk about butrans
No comments yet. Questions, tips, what worked for you - start the conversation.